As the world watches and waits for a vaccine, we ask what IR is like under the pandemic spotlight
‘The scrutiny is extraordinarily high,’ says Nick Mazing, director of research at Sentieo, talking about the media and market focus on pharmaceuticals and biotech firms involved in the fight against Covid-19. ‘And it’s not just scrutiny. It is interference.’
As the world waits with hope for big pharma and its smaller, more dynamic biotech cousins to free us from the confines of the coronavirus, the companies involved in producing vaccines or therapeutics have seen demanding new stakeholders
To continue reading you need an active subscription
Subscribe- Quarterly issues of IR Magazine
- Unlimited Articles online
- Newsletter
- Investor Perception Studies – Europe, US, Canada and Asia
- Strategy guides
- Whitepapers
- Benchmarking reports
From
$995*
Garnet Roach
Garnet Roach joined IR Magazine in October 2012, working on both the editorial and research sides of the publication. Prior to entering the world of investor relations, her freelance career covered a broad range of subjects, from technology to...
Senior reporter
